Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study

Sauck, Anja; Keller, Isabelle; Hainc, Nicolin; Pfofe, Denis; Najafi, Arash; John, Hubert; Hohmann, Joachim

doi:10.3390/tomography8040169

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modern prostate biopsy techniques are based on the computerised 3D merging of the ultrasound and MRI images to provide better vision during the procedure (Fusion Biopsy) [ 9 , 10 ]. However, the method is expensive due to high equipment costs.…”

Section: Introductionmentioning

confidence: 99%

Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion

et al. 2023

View full text Add to dashboard Cite

Prostate cancer is among the most frequently diagnosed cancers and a leading cause of cancer-related death in men. Currently, the most reliable and widely used imaging test for prostate cancer diagnosis is multiparametric pelvic magnetic resonance imaging (mpMRI). Modern biopsy techniques are based on the computerised merging of ultrasound and MRI images to provide better vision during the biopsy procedure (Fusion Biopsy). However, the method is expensive due to high equipment cost. Cognitive fusion of ultrasound and MRI images has recently emerged as a cheaper and easier alternative to computerised fusion. The aim of this prospective study is to perform an in-patient comparison of the systematic prostate biopsy procedure (SB) vs. cognitive fusion (CF) guided prostate biopsy method in terms of safety, ease of use, cancer detection rate and clinically significant cancer detection. We enrolled 103 patients with suspected prostate cancer that were biopsy naive, with PSA > 4 ng/dL and PIRADS score of 3, 4 or 5. All patients received a transperineal standard 12–18 cores systematic biopsy (SB) and a four-cores targeted cognitive fusion (CF) biopsy. Following the prostate biopsy, 68% of the patients were diagnosed with prostate cancer (70/103 patients). SB diagnosis rate was 62% while CF biopsy was slightly better with a 66% rate. There was a significant 20% increase in clinically significant prostate cancer detection rate for the CF compared to SB (p < 0.05) and a significant prostate cancer risk upgrade from the low to the intermediate risk category (13%, p = 0.041). Transperineal cognitive fusion targeted prostate biopsy is a straightforward biopsy method that is easy to perform and is a safe alternative to standard systematic biopsy with improved significant cancer detection accuracy. A combined targeted and systematic approach should be used for the best diagnostic results.

show abstract

Section: Introductionmentioning

confidence: 99%

Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The volume of the lesions was significantly correlated with ISUP grades. The authors concluded that the PI-RADS v2 score and lesion volume were associated with the presence and clinical significance of prostate cancer, but that there was not an insignificant number of false positive findings [ 4 ].…”

mentioning

confidence: 99%

New Frontiers in Oncological Imaging

et al. 2023

View full text Add to dashboard Cite

show abstract

Precision in prostate cancer detection: integrating prostate-specific antigen density (PSAD) and the Prostate Imaging Reporting and Data System (PI-RADS) to provide additional risk stratification for a more accurate diagnostic decision

Hrubá,

Kubas,

Franko

et al. 2024

Ir J Med Sci

View full text Add to dashboard Cite

Purpose This study focuses on integrating prostate-specific antigen density (PSAD) and Prostate Imaging Reporting and Data System (PI-RADS) for enhanced risk stratification in biopsy-naïve patients. Methods A prospective study was conducted on 339 patients with suspected prostate cancer, utilizing PSAD and PI-RADS in combination. Logistic regression models were employed, and receiver operating characteristic (ROC) analysis performed to evaluate predictive performance. The patient cohort underwent multiparametric MRI, targeted biopsy, and systematic biopsy. Results When patients were stratified into four PSAD risk groups, the rate of clinically significant prostate cancer (csPCa) increased significantly with higher PSAD levels. Logistic regression confirmed the independent contribution of PI-RADS and PSAD, highlighting their role in the prediction of csPCa. Combined models showed superior performance, as evidenced by the area under the curve (AUC) for PI-RADS category and PSAD (0.756), which exceeded that of the individual predictors (PSA AUC, 0.627, PI-RADS AUC 0.689, PSAD AUC 0.708). Conclusion This study concludes that combining PSAD and PI-RADS improves diagnostic accuracy and predictive value for csPCa in biopsy-naïve men, resulting in a promising strategy to provide additional risk stratification for more accurate diagnostic decision in biopsy-naïve patients, especially in the PI-RADS 3 group.

show abstract

Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study

Cited by 3 publications

References 33 publications

Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion

Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion

New Frontiers in Oncological Imaging

Precision in prostate cancer detection: integrating prostate-specific antigen density (PSAD) and the Prostate Imaging Reporting and Data System (PI-RADS) to provide additional risk stratification for a more accurate diagnostic decision

Contact Info

Product

Resources

About